[ad_1]
New Delhi: Glenmark Pharmaceuticals said on Monday that it would launch Cancer Treatment Drug Zanbrutiinib after approval by Drugs Controller General of India (DCGI) in India.
Zanubrutinib will be marketed under the brand name Brookins in India.
It is the first and only brutton tyrosine inhibitor approved in India for the treatment of five different B-cell deformities (BTK) inhibitors: chronic lymphocytic leukemia/small lymphocytic lymphoma, waldenstrom macoglobulinmia, mental cell lymphoma, marginal zone lymphoma, and
Chairman and Business Head of Glenmark Pharmaceuticals – India Formulation Alok Malik said, “We are ready to bring Brookins to India in the coming months, which is as part of our ongoing partnership with Begze (now Beon Medicine).”
He said that the launch is an important milestone in our innovative oncology portfolio, providing patients in India to reliable medicine globally with perfect efficacy and safety. Glenmark shares ended 0.68 percent on Monday 1,600.85 episi on BSE.
[ad_2]


